Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Wimberger P Roth C

    2020-08-18


    [9] Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, and Schwarzenbach H (2011). Impact of platinum-based chemotherapy on circulating nucleic Iberiotoxin levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer 128, 2572–2580.
    [11] Gascoigne KE and Taylor SS (2008). Cancer cells display profound intra- and
    interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111–122.
    [14] Waters JC, Mitchison TJ, Rieder CL, and Salmon ED (1996). The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol Biol Cell 7, 1547–1558.
    [20] Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, Hathaway N, Dimova N, Cuny GD, and King RW (2010). Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 18, 382–395.
    [23] Lee KS and Erikson RL (1997). Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol Cell Biol 17, 3408–3417.
    [24] Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H, and Strebhardt K (1997). Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14, 543–549.
    [25] Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, and Bleyl U (2000). Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 196, 753–759.
    [32] Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, and Matsunaga T, et al (2004). Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23, 5901–5911.
    [34] Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, von Minckwitz G, Kaufmann M, and Strebhardt K (2002). Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21, 3162–3171.
    [36] Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, and Strebhardt K (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96, 862–872.
    [38] Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, and Miyakawa I (2001). Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 164, 41–49.
    [39] Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, and Follana P, et al (2016). Volasertib versus chemotherapy in platinum-resistant or -refractory ovarian cancer: a randomized phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. J Clin Oncol 34, 706–713.
    [40] Rieder CL and Maiato H (2004). Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7, 637–651. [41] Yamada HY and Gorbsky GJ (2006). Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol Cancer Ther 5, 2963–2969.
    [42] Huang HC, Shi J, Orth JD, and Mitchison TJ (2009). Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16, 347–358. [43] McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, and Statistics Subcommittee of the NCIEWGoCD (2005). REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2, 416–422.
    [44] Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, and Yong M, et al (2015). Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun 6, 7419. [45] Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, and Adler T, et al (2011). Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2, 395.
    [46] Helmke C, Raab M, Rodel F, Matthess Y, Oellerich T, Mandal R, Sanhaji M, Urlaub H, Rodel C, and Becker S, et al (2016). Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. Cell Res 26, 914–934. [47] Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, and Adolf GR (2009). BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    [51] Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, and Bonazzi C, et al (2003). International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95, 125–132.